{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:59:34Z","timestamp":1779893974994,"version":"3.53.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Regional Development Fund through the Interreg Deutschland-Danmark program","award":["087-1.1-18"],"award-info":[{"award-number":["087-1.1-18"]}]},{"name":"European Regional Development Fund through the Interreg Deutschland-Danmark program","award":["087-1.1-18"],"award-info":[{"award-number":["087-1.1-18"]}]},{"name":"European Regional Development Fund through the Interreg Deutschland-Danmark program","award":["087-1.1-18"],"award-info":[{"award-number":["087-1.1-18"]}]},{"name":"European Regional Development Fund through the Interreg Deutschland-Danmark program","award":["087-1.1-18"],"award-info":[{"award-number":["087-1.1-18"]}]},{"name":"European Regional Development Fund through the Interreg Deutschland-Danmark program","award":["087-1.1-18"],"award-info":[{"award-number":["087-1.1-18"]}]},{"DOI":"10.13039\/501100004168","name":"Universit\u00e4t zu L\u00fcbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004168","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Radiotherapy of head-and-neck cancer (SCCHN) is often associated with acute toxicity. In a previous trial, daily reminders by staff members to perform skin care resulted in less dermatitis. This randomized trial investigated whether a mobile application can replace these reminders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients were stratified according to tumor site, treatment and center. Fifty-three patients were eligible for per-protocol-set (25 with, 28 without app). Primary endpoint was grade\u2009\u2265\u20092 dermatitis until 60\u00a0Gy. Secondary endpoints included dermatitis grade\u2009\u2265\u20092 until end of radiotherapy (EOT), dermatitis grade\u2009\u2265\u20093, and mucositis grade\u2009\u2265\u20092 and\u2009\u2265\u20093.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After an interim analysis, the study was terminated (delayed and slow accrual). Until 60\u00a0Gy, grade\u2009\u2265\u20092 dermatitis rates were 72% with vs. 82% without app (<jats:italic>p<\/jats:italic>\u2009=\u20090.38), grade\u2009\u2265\u20093 dermatitis rates 20% vs. 11% (<jats:italic>p<\/jats:italic>\u2009=\u20090.45). Until EOT, grade\u2009\u2265\u20092 and\u2009\u2265\u20093 dermatitis rates were 72% vs. 86% (<jats:italic>p<\/jats:italic>\u2009=\u20090.22) and 24% vs. 18% (<jats:italic>p<\/jats:italic>\u2009=\u20090.58). Until 60\u00a0Gy, grade\u2009\u2265\u20092 and\u2009\u2265\u20093 mucositis rates were 76% vs. 82% (<jats:italic>p<\/jats:italic>\u2009=\u20090.58) and 20% vs. 36% (<jats:italic>p<\/jats:italic>\u2009=\u20090.20). Until EOT, corresponding mucositis rates were 76% vs. 82% (<jats:italic>p<\/jats:italic>\u2009=\u20090.58) and 28% vs. 43% (<jats:italic>p<\/jats:italic>\u2009=\u20090.26).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Given the limitations of this trial, the reminder app led to non-significant reduction of grade\u2009\u2265\u20092 dermatitis, grade\u2009\u2265\u20092 mucositis and\u2009\u2265\u20093 mucositis. Additional studies are required to define the value of reminder apps during radiotherapy for SCCHN.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10088-3","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T07:02:27Z","timestamp":1663398147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of a mobile application (reminder app) on acute toxicity during radiotherapy of head-and-neck cancer \u2013 results of a randomized phase III trial (RAREST-02)"],"prefix":"10.1186","volume":"22","author":[{"given":"Dirk","family":"Rades","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Cacicedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl L.","family":"Bruchhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer G.","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Olbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Schild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soeren","family":"Tvilsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"key":"10088_CR1","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ijrobp.2010.03.033","volume":"80","author":"D Rades","year":"2011","unstructured":"Rades D, Kronemann S, Meyners T, Bohlen G, Tribius S, Kazic N, Schroeder U, Hakim SG, Schild SE, Dunst J. Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III\/IV squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2011;80:1037\u201344.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10088_CR2","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ijrobp.2007.07.2380","volume":"70","author":"D Rades","year":"2008","unstructured":"Rades D, Stoehr M, Kazic N, Hakim SG, Walz A, Schild SE, Dunst J. Locally advanced stage IV squamous cell carcinoma of the head and neck: impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:1108\u201314.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10088_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ijrobp.2009.08.004","volume":"78","author":"MD Fesinmeyer","year":"2010","unstructured":"Fesinmeyer MD, Mehta V, Blough D, Tock L, Ramsey SD. Effect of radiotherapy interruptions on survival in medicare enrollees with local and regional head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010;78:675\u201381.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10088_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12885-018-4119-x","volume":"18","author":"C Narvaez","year":"2018","unstructured":"Narvaez C, Doemer C, Idel C, Setter C, Olbrich D, Ujmajuridze Z, Carl JH, Rades D. Radiotherapy related skin toxicity (RAREST-01): Mepitel\u00ae film versus standard care in patients with locally advanced head-and-neck cancer. BMC Cancer. 2018;18:197.","journal-title":"BMC Cancer"},{"key":"10088_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.radonc.2019.07.023","volume":"139","author":"D Rades","year":"2019","unstructured":"Rades D, Narvaez CA, Splettst\u00f6\u00dfer L, D\u00f6mer C, Setter C, Idel C, Ribbat-Idel J, Perner S, Bartscht T, Olbrich D, Schild SE, Carl J. A randomized trial (RAREST-01) comparing Mepitel\u00ae film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN). Radiother Oncol. 2019;139:79\u201382.","journal-title":"Radiother Oncol"},{"key":"10088_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s13063-020-04307-0","volume":"21","author":"D Rades","year":"2020","unstructured":"Rades D, Narvaez CA, Doemer C, Janssen S, Olbrich D, Tvilsted S, Conde-Moreno AJ, Cacicedo J. Radiotherapy-related skin toxicity (RAREST-02): A randomized trial testing the effect of a mobile application reminding head-and-neck cancer patients to perform skin care (reminder app) on radiation dermatitis. Trials. 2020;21:424.","journal-title":"Trials"},{"key":"10088_CR7","unstructured":"National Institutes of Health\/National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. National Institutes of Health\/National Cancer Institute 2010."},{"key":"10088_CR8","unstructured":"RTOG: http:\/\/www.rtog.org\/"},{"key":"10088_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9 Suppl","key":"10088_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/cncr.20162","volume":"100","author":"ST Sonis","year":"2004","unstructured":"Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology: Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl):1995\u20132025.","journal-title":"Cancer"},{"key":"10088_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s00066-008-1825-3","volume":"184","author":"D Rades","year":"2008","unstructured":"Rades D, Stoehr M, Meyners T, Bohlen G, Nadrowitz R, Dunst J, Schild SE, Wroblewski J, Albers D, Schmidt R, Alberti W, Tribius S. Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer. Strahlenther Onkol. 2008;184:198\u2013205.","journal-title":"Strahlenther Onkol"},{"key":"10088_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00066-009-1992-x","volume":"185","author":"S Tribius","year":"2009","unstructured":"Tribius S, Kronemann S, Kilic Y, Schroeder U, Hakim S, Schild SE, Rades D. Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2009;185:675\u201381.","journal-title":"Strahlenther Onkol"},{"key":"10088_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.oraloncology.2006.05.006","volume":"43","author":"D Rades","year":"2007","unstructured":"Rades D, Fehlauer F, Wroblesky J, Albers D, Schild SE, Schmidt R. Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy. Oral Oncol. 2007;43:535\u201343.","journal-title":"Oral Oncol"},{"key":"10088_CR14","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1093\/jnci\/91.24.2081","volume":"91","author":"G Calais","year":"1999","unstructured":"Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"10088_CR15","doi-asserted-by":"publisher","first-page":"100223","DOI":"10.1016\/j.ctarc.2020.100223","volume":"25","author":"N Kucha","year":"2020","unstructured":"Kucha N, Soni TP, Jakhotia N, Patni N, Singh DK, Gupta AK, Sharma LM, Goyal J. A prospective, comparative analysis of acute toxicity profile between three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) in locally advanced head and neck cancer patients. Cancer Treat Res Commun. 2020;25:100223.","journal-title":"Cancer Treat Res Commun"},{"key":"10088_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3857\/roj.2020.01018","volume":"39","author":"A Grover","year":"2021","unstructured":"Grover A, Soni TP, Patni N, Singh DK, Jakhotia N, Gupta AK, Sharma LM, Sharma S, Gothwal RS. A randomized prospective study comparing acute toxicity, compliance and objective response rate between simultaneous integrated boost and sequential intensity-modulated radiotherapy for locally advanced head and neck cancer. Radiat Oncol J. 2021;39:15\u201323.","journal-title":"Radiat Oncol J"},{"key":"10088_CR17","first-page":"e16505","volume":"13","author":"S Venkateshulu","year":"2021","unstructured":"Venkateshulu S, Br KK. A study comparing acute toxicities of cetuximab and cisplatin in patients undergoing definitive chemoradiation with intensity-modulated radiotherapy for locally advanced carcinoma of head and neck. Cureus. 2021;13:e16505.","journal-title":"Cureus"},{"key":"10088_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.rpor.2015.05.010","volume":"20","author":"JA Gonz\u00e1lez Ferreira","year":"2015","unstructured":"Gonz\u00e1lez Ferreira JA, Ja\u00e9n Olasolo J, Azinovic I, Jeremic B. Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature. Rep Pract Oncol Radiother. 2015;20:328\u201339.","journal-title":"Rep Pract Oncol Radiother"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10088-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10088-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10088-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T19:19:31Z","timestamp":1663442371000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10088-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10088"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10088-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,17]]},"assertion":[{"value":"2 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved by the responsible ethics committees in L\u00fcbeck, Hannover and Barakaldo (initial approval by the ethics committee at the University of L\u00fcbeck, reference number 19\u2013302). It was conducted in accordance with the principles laid out in the Declaration of Helsinki and the principles of Good Clinical Practice (ICH-GCP E6). Patients were included after having given written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dirk Rades and Stefan Janssen belong to the editorial board of BMC Cancer; otherwise, they have no competing interest related to this trial. Other authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"989"}}